As part of CRA’s issues leadership initiative to challenge industry thinking on rare diseases, we assembled a panel of CRA experts to discuss the opportunities and challenges posed by the latest therapeutic breakthroughs in conditions that affect fewer than one in 2,000 people. Neil Turner moderates a discussion with Greg Bell, Kevin Brubacher, Ned Kitfield, Cécile Matthews, and Tim Wilsdon.
Contracting schemes in medtech: Challenges and opportunities
Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented...